Literature DB >> 25388271

Mouse models of allergic asthma.

Matthew Gold1, David Marsolais, Marie-Renee Blanchet.   

Abstract

In the last 20 years, the development of murine models of allergic asthma has provided researchers with a means to explore the mechanisms of this T-helper type 2 (Th2)-driven inflammatory disease. While systemic sensitization and airway challenge with ovalbumin has been the most widely used model, recent emphasis has been placed on the development of models using more naturally occurring antigens. However, the diversity of models currently available makes it hard for investigators new to this field to choose to use the most effective and appropriate model to test their hypothesis. Here we describe three different mouse models of allergic asthma, including the classical ovalbumin model, a modified ovalbumin model that has been shown to be mast-cell dependent, as well as a house dust mite antigen-induced model. We also discuss briefly their characterization and differences, in the aim to facilitate the choice of the appropriate model when working on this intricate Th2 inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25388271     DOI: 10.1007/978-1-4939-1568-2_31

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  Downregulation of SUMF2 gene in ovalbumin-induced rat model of allergic inflammation.

Authors:  Chuanfeng Fang; Xiaoxia Li; Hongyan Liang; Li Xue; Lei Liu; Chun Yang; Guangqiang Gao; Xiaofeng Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP-VPAC2 signalling pathway.

Authors:  Muhua Huang; Jinfeng Wu; Jingcheng Dong
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

3.  Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation.

Authors:  Christopher B Medina; Yu-Hsin Chiu; Marta E Stremska; Christopher D Lucas; Ivan Poon; Kenneth S Tung; Michael R Elliott; Bimal Desai; Ulrike M Lorenz; Douglas A Bayliss; Kodi S Ravichandran
Journal:  Immunity       Date:  2021-07-21       Impact factor: 43.474

4.  Pharmaceutical Benefits of Fluticasone Propionate Association to Delivery Systems: In Vitro and In Vivo Evaluation.

Authors:  Marina G Dogbe; Ambinintsoa Yattussia Mafilaza; Carla Vânia Eleutério; Helena Cabral-Marques; Sandra Simões; Maria Manuela Gaspar
Journal:  Pharmaceutics       Date:  2019-10-10       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.